On May 19, local time, global chemical giant Covestro announced a force majeure for all MDI products in North America, due to sudden and unforeseen production failures. Market messages simultaneously ...

If Python developers have one consistent gripe about their beloved language, it tends to be this: Why is it so hard to take a Python program and deploy it as a standalone artifact, the way C, C++, ...

MDI guard James Witham dribbles the ball against Brewer forward Oli Higgins. Credit: Matt Junker / BDN Monday night featured a clash between two of the best boys basketball players in Maine’s North ...

Trust in AI begins when leaders admit what they do not know, address fears, and help people adapt. In partnership withInfosys Topaz Rolling out enterprise-grade AI means climbing two steep cliffs at ...

Medetomidine, a veterinary sedative, mixed into fentanyl has sent thousands to hospitals, not only for overdose but for life-threatening withdrawal. It is spreading to other cities. Joseph is newly in ...

With short-form video now dominant on social media, researchers are racing to understand how the highly engaging, algorithm-driven format may be reshaping the brain. Limited time: Save 25% on NBC News ...

The Federal Reserve will end Quantitative Tightening on December 1st, halting SOMA portfolio reductions after a $2.4 trillion shrinkage since June 2022. Money market conditions signal reserve levels ...

Long QT syndrome is a leading cause of sudden death in young persons, with a prevalence exceeding 1 in 2000. It is characterized by prolongation of the QT interval, aberrant T-wave morphologic ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...

The artificial intelligence boom is quickly becoming the largest wealth creation spree in recent history. That's boosted in part by blockbuster fundraising rounds this year for Anthropic, Safe ...

In an Aug. 7 earnings call, Eli Lilly CEO David Ricks told investors that the company plans to submit the drug, orforglipron, to the FDA for approval by the end of the year. Dan Skovronsky, chief ...